免疫检查点抑制剂作为接受移植后环磷酰胺方案异基因移植的桥接治疗
该回顾性研究纳入14例连续患者,在减低强度预处理、T细胞充足异基因血液或骨髓移植(alloBMT)前以免疫检查点抑制剂(ICI)作为最后挽救治疗,所有患者均接受移植后环磷酰胺(PTCy)预防移植物抗宿主病(GvHD)。结果为无3-4级急性GvHD,6例2级急性GvHD经免疫抑制治疗均缓解,无肝静脉闭塞病、其他免疫相关不良事件、慢性GvHD或非复发死亡;中位随访15个月,2例复发,14例中12例存活且无进展,唯一死亡原因为疾病复发。作者认为尽管需要更多经验,对ICI相关免疫并发症的担忧不应妨碍以PTCy为GvHD预防的异基因骨髓移植。
要点
- 14例接受ICI桥接后行PTCy方案alloBMT的患者中无3-4级急性GvHD。
- 6例2级急性GvHD经免疫抑制治疗均缓解,无慢性GvHD或非复发死亡。
- 中位随访15个月,2例复发,14例中12例存活且无进展。
核心结论
- 作者认为,尽管需要更多经验,对ICI相关免疫并发症的担忧不应妨碍以PTCy为GvHD预防的异基因骨髓移植。
研究设计与样本
- 回顾性综述14例连续患者,在减低强度预处理、T细胞充足alloBMT前以ICI作为最后挽救治疗,所有患者均接受PTCy。
主要发现
- 无3-4级急性GvHD,所有6例2级急性GvHD经免疫抑制治疗均缓解。
- 无患者发生肝静脉闭塞病、其他免疫相关不良事件、慢性GvHD或非复发死亡。
- 中位随访15个月,2例复发,14例中12例存活、状况良好且无进展。
- 唯一死亡原因为疾病复发。
局限性
- 原文述Although more experience is needed。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Published reports suggest that immune checkpoint inhibitors (ICIs) before allogeneic blood or marrow transplantation (alloBMT) may increase the incidence of graft-versus-host disease (GvHD), immune-related adverse events, and nonrelapse mortality (NRM); this led to the US Food and Drug Administration issuing a "Warning and Precaution" regarding the potential for life-threatening immune-mediated complications associated with alloBMT after nivolumab and pembrolizumab. We retrospectively reviewed the outcomes of 14 consecutive patients who received ICIs as their final salvage therapy before T-cell-replete alloBMT using reduced-intensity conditioning. All patients received posttransplant cyclophosphamide (PTCy), which significantly limits severe GvHD, even in the mismatched-donor setting. There was no grade 3-4 acute GvHD (aGvHD), and all 6 cases of grade 2 aGvHD readily resolved with immunosuppression. No patient experienced veno-occlusive disease of the liver, other immune-related adverse events, chronic GvHD, or NRM. There have been 2 relapses (15-month median follow-up), with 12 of 14 patients remaining alive, well, and progression-free. The only death was a result of disease relapse. Although more experience is needed, our data suggest that concerns over immunologic complications associated with ICIs should not preclude allogeneic bone marrow transplantation with PTCy as GvHD prophylaxis.
引用
- Schoch LK, Cooke KR, Wagner-Johnston ND, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018. PMID: 30190282. doi:10.1182/bloodadvances.2018019208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。